このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Gland Pharma バランスシートの健全性

財務の健全性基準チェック /56

Gland Pharmaの総株主資本は₹87.2B 、総負債は₹3.2Bで、負債比率は3.7%となります。総資産と総負債はそれぞれ₹106.6Bと₹19.4Bです。 Gland Pharmaの EBIT は₹9.9Bで、利息カバレッジ比率37.7です。現金および短期投資は₹18.4Bです。

主要情報

3.7%

負債資本比率

₹3.20b

負債

インタレスト・カバレッジ・レシオ	37.7x
現金	₹18.39b
エクイティ	₹87.24b
負債合計	₹19.37b
総資産	₹106.61b

財務の健全性に関する最新情報

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19

Recent updates

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

May 25

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14

Gland Pharma Limited (NSE:GLAND) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 19

Gland Pharma Limited's (NSE:GLAND) 27% Price Boost Is Out Of Tune With Earnings

Mar 04

Gland Pharma Limited's (NSE:GLAND) Stock Is Going Strong: Is the Market Following Fundamentals?

Feb 20

財務状況分析

短期負債: GLANDの短期資産 ( ₹56.5B ) が短期負債 ( ₹14.0B ) を超えています。

長期負債: GLANDの短期資産 ( ₹56.5B ) が長期負債 ( ₹5.4B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: GLAND総負債よりも多くの現金を保有しています。

負債の削減: GLANDの負債対資本比率は、過去 5 年間で0.2%から3.7%に増加しました。

債務返済能力: GLANDの負債は営業キャッシュフローによって十分にカバーされています ( 311.7% )。

インタレストカバレッジ: GLANDの負債に対する利息支払いは EBIT ( 37.7 x coverage) によって十分にカバーされています。

Gland Pharma バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Recent updates

Insider recently sold ₹24m worth of stock

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million

Head of Quality recently sold ₹8.3m worth of stock

Insider recently sold ₹9.2m worth of stock

Gland Pharma Limited Announces Management Changes

Insufficient new directors

Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively

Consensus EPS estimates fall by 14%, revenue upgraded

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

Gland Pharma Limited, Annual General Meeting, Aug 30, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q4, 2024 Results on May 22, 2024

Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024

Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals

Chief Technical Officer recently sold ₹14m worth of stock

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Chief Operating Officer recently sold ₹2.8m worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

New minor risk - Insider selling

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2024 Results on Nov 06, 2023

Chief Technical Officer recently sold ₹10m worth of stock

Gland Pharma Limited Appoints Ankit Gupta as Vice-President (Strategy & Investments)

Investor sentiment improves as stock rises 23%

Gland Pharma Limited Appoints Prakash Vithal Baliga as Chief Operating Officer

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q1, 2024 Results on Aug 07, 2023

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 12% to ₹1,520

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Gland Pharma Limited, Annual General Meeting, Aug 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently sold ₹683k worth of stock

Investor sentiment improves as stock rises 16%

Insider recently sold ₹756k worth of stock

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Price target decreased by 13% to ₹2,119

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q3, 2023 Results on Jan 23, 2023

Insider recently sold ₹798k worth of stock

Insider recently sold ₹869k worth of stock

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2023 Results on Oct 26, 2022

Insider recently sold ₹4.1m worth of stock

Insider recently sold ₹2.3m worth of stock

Gland Pharma Limited Announces Xiaohui Guan and Yifang Wu Not Offer for Reappointment as Directors

Insider recently sold ₹1.6m worth of stock

Insider recently sold ₹1.4m worth of stock

Insider recently sold ₹2.3m worth of stock

Consensus revenue estimates fall by 16%

Price target decreased to ₹3,033

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Gland Pharma Limited to Report Q1, 2023 Results on Jul 20, 2022

Insider recently sold ₹7.1m worth of stock

Insider recently sold ₹17m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Gland Pharma Limited, Annual General Meeting, Aug 30, 2022

High number of new directors

Gland Pharma Limited to Report Q4, 2022 Results on May 19, 2022

Senior Vice President of R&D recently sold ₹19m worth of stock

Insider recently sold ₹660k worth of stock

財務の健全性基準チェック /56